Sai Parenteral's IPO Day 2: Check GMP, Subscription Status & Key Highlights
The Sai Parenteral's IPO enters its second day of subscription today, 25 March 2026. By the end of the first day, the issue was subscribed to 0.05 times overall. The bidding window is scheduled to close on March 27, 2026.
Sai Parenteral's IPO: Issue Details
Issue Type: Sai Parenteral's IPO is a book-building issue of ₹408.79 crore, consisting of a fresh issue of ₹285 crore and an offer for sale of ₹123.79 crore.
Price Band: The price band is set between ₹372 and ₹392 per share.
Lot Size & Minimum Investment: The lot size for an application is 38 shares, and the minimum investment required is ₹14,896 (for retail investors).
Allotment Date: The basis of allotment will be finalised by March 30, 2026
Listing Date: The tentative listing date on NSE and BSE is April 2, 2026.
Book-running Lead Managers: Arihant Capital Markets Limited
Registrar: Bigshare Services Private Limited
Sai Parenteral's IPO Day 2 Subscription Status
[25-March-2026 11:54:00 hrs]
|
Investor Category |
Subscription (Times) |
|
Qualified Institutional Buyers (QIBs) |
0.02 |
|
Non-Institutional Investors |
0.18 |
|
Retail Individual Investors (RIIs) |
0.04 |
|
Total |
0.06 |
Utilisation of IPO Proceeds
The net proceeds from the fresh issue will be used to fund the expenses towards the following objectives:
- Capacity expansion and upgradation of manufacturing facilities
- Establishment of a new R&D Centre
- Repay/prepay outstanding borrowings
- Repayment of bridge loan and term loan availed for investment in wholly owned subsidiary, Sai Parenterals Pte Limited (Singapore), in relation to the acquisition of Noumed Pharmaceuticals Pty Limited (Australia)
- Fund working capital requirements
- General corporate purposes
Explore other Upcoming IPOs on BSE and NSE.
Sai Parenteral's IPO GMP
According to media reports, the Grey Market Premium (GMP) for Sai Parenteral's IPO is ₹0 over the IPO price.
Sai Parenteral's Business Overview
Sai Parenterals is a pharmaceutical formulations company engaged in the development, manufacturing, and commercialisation of a wide range of healthcare products. The company operates across two primary verticals: (i) branded generic formulations and (ii) contract development and manufacturing organisation (CDMO) services, catering to both domestic and international markets.
The company owns and operates five manufacturing facilities in India, out of which four are based in Hyderabad, Telangana. These facilities are compliant with various quality and regulatory standards, including GMP, WHO-GMP, and international accreditations such as TGA and PIC/S for select units.
Check out newly Listed IPOs on BSE and NSE.
Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.
To read the RA disclaimer, please click here.